Anthrax vaccine - Panacea Biotec

Drug Profile

Anthrax vaccine - Panacea Biotec

Alternative Names: Recombinant anthrax vaccine - Panacea Biotec

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jawaharlal Nehru University
  • Developer Panacea Biotec
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anthrax

Most Recent Events

  • 20 Apr 2016 No recent reports on development identified - Phase-II for Anthrax (Prevention) in India (Parenteral)
  • 01 Jan 2013 Phase-II clinical trials in Anthrax (prevention) in India (Parenteral)
  • 01 Jan 2008 Preclinical trials in Anthrax in India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top